uORF-targeting steric block antisense oligonucleotides do not reproducibly increase RNASEH1 expression
Ahlskog N. et al, (2025), Molecular Therapy - Nucleic Acids, 36, 102406 - 102406
Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy.
Chwalenia K. et al, (2025), J Muscle Res Cell Motil
An extracellular vesicle delivery platform based on the PTTG1IP protein.
Martin Perez C. et al, (2024), Extracell Vesicle, 4
Long-term dystrophin restoration supports development of splice correction therapy for DMD patients with exon 2 duplications
Roberts TC., (2023), Molecular Therapy Methods and Clinical Development, 31
EV-mediated promotion of myogenic differentiation is dependent on dose, collection medium, and isolation method
Hanson B. et al, (2023), Molecular Therapy - Nucleic Acids, 33, 511 - 528
Therapeutic approaches for Duchenne muscular dystrophy.
Roberts TC. et al, (2023), Nat Rev Drug Discov
Investigating Eukaryotic Elongation Factor 2 Kinase/Eukaryotic Translation Elongation Factor 2 Pathway Regulation and Its Role in Protein Synthesis Impairment during Disuse-Induced Skeletal Muscle Atrophy.
Vilchinskaya N. et al, (2023), Am J Pathol, 193, 813 - 828
Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD.
Hanson B. et al, (2022), Mol Ther Nucleic Acids, 30, 379 - 397
Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties.
Chwalenia K. et al, (2022), Mol Ther Nucleic Acids, 29, 955 - 968
AR cooperates with SMAD4 to maintain skeletal muscle homeostasis.
Forouhan M. et al, (2022), Acta Neuropathol, 143, 713 - 731
Nuclear microRNA-466c regulates Vegfa expression in response to hypoxia
Laitinen P. et al, (2022), PLoS ONE, 17
Enhancing the Therapeutic Potential of Extracellular Vesicles Using Peptide Technology
Martin Perez C. et al, (2022), Methods in Molecular Biology, 2383, 119 - 141